A review of 2022 Chinese clinical guidelines on the management of hepatocellular carcinoma: updates and insights.

ABSTRACT: Significant improvements in the management of hepatocellular carcinoma (HCC) during the past three years have urged the timely update of clinical guidelines in China. In brief, aMAP score is newly recommended as an effective risk stratification tool to predict HCC occurrence especially for non-cirrhotic patients. Biomarker-based surveillance including 7 micro-RNA panel and GALAD score are advocated to assist early diagnosis. China liver cancer (CNLC) staging system proposed in the 2017 guideline continues to be the standard model for staging with modifications in the treatment allocations. Conversion therapies using multi-modal, high intensity strategies are advocated to facilitate subsequent resection for patients with technically unresectable CNLC stage Ia, Ib, IIa HCC, or technically re

SUBMITTER: Xie DY 

PROVIDER: S-EPMC10129899 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature